TY - JOUR
T1 - Adverse drug reaction management in hospital settings
T2 - review on practice variations, quality indicators and education focus
AU - Aung, Ar Kar
AU - Walker, Steven
AU - Khu, Yin Li
AU - Tang, Mei Jie
AU - Lee, Jennifer I.
AU - Graudins, Linda Velta
N1 - Funding Information:
We thank Dr Daniel mazzoni and Dr Tess Aitken for their perspectives and contributions to improve the quality and content of this manuscript.
Publisher Copyright:
© 2022, Crown.
PY - 2022/5
Y1 - 2022/5
N2 - Purpose: Adverse drug reactions (ADRs) contribute significantly to healthcare burden. However, they are largely preventable through appropriate management processes. This narrative review aims to identify the quality indicators that should be considered for routine monitoring of processes within hospital ADR management systems. It also examines the potential reasons behind variation in ADR management practices amongst HCPs, and explores possible solutions, focusing on targeted education programmes, to improve both the quality and quantity indicators of ADR management processes. Methods: A comprehensive literature review was conducted to explore relevant themes and topics concerning ADR management, quality indicators and educational interventions. Results: Substantial variability exists in ADR management amongst healthcare professionals (HCPs) with regard to reporting rates, characteristics of ADRs reported, quality of assessment, completeness of reports and, most importantly, risk communication practices. These variable practices not only threaten patient safety but also undermine pharmacovigilance processes. To date, quality indicators to monitor ADR management practices within hospital settings remain ill-defined. Furthermore, evidence behind effective interventions, especially in the form of targeted education strategies, to improve the quality of ADR management remains limited. Conclusions: The focus of ADR management in hospitals should be to promote patient safety through comprehensive assessment, risk communication and safe prescribing. There is a need to develop a system to define, measure and monitor the quality of ADR management. Educational strategies may help improve the quality of ADR management processes.
AB - Purpose: Adverse drug reactions (ADRs) contribute significantly to healthcare burden. However, they are largely preventable through appropriate management processes. This narrative review aims to identify the quality indicators that should be considered for routine monitoring of processes within hospital ADR management systems. It also examines the potential reasons behind variation in ADR management practices amongst HCPs, and explores possible solutions, focusing on targeted education programmes, to improve both the quality and quantity indicators of ADR management processes. Methods: A comprehensive literature review was conducted to explore relevant themes and topics concerning ADR management, quality indicators and educational interventions. Results: Substantial variability exists in ADR management amongst healthcare professionals (HCPs) with regard to reporting rates, characteristics of ADRs reported, quality of assessment, completeness of reports and, most importantly, risk communication practices. These variable practices not only threaten patient safety but also undermine pharmacovigilance processes. To date, quality indicators to monitor ADR management practices within hospital settings remain ill-defined. Furthermore, evidence behind effective interventions, especially in the form of targeted education strategies, to improve the quality of ADR management remains limited. Conclusions: The focus of ADR management in hospitals should be to promote patient safety through comprehensive assessment, risk communication and safe prescribing. There is a need to develop a system to define, measure and monitor the quality of ADR management. Educational strategies may help improve the quality of ADR management processes.
KW - Adverse drug reactions
KW - Education strategies
KW - Management
KW - Practice variations
KW - Quality
KW - Reporting
UR - http://www.scopus.com/inward/record.url?scp=85124846173&partnerID=8YFLogxK
U2 - 10.1007/s00228-022-03287-1
DO - 10.1007/s00228-022-03287-1
M3 - Review Article
C2 - 35171316
AN - SCOPUS:85124846173
SN - 0031-6970
VL - 78
SP - 781
EP - 791
JO - European Journal of Clinical Pharmacology
JF - European Journal of Clinical Pharmacology
IS - 5
M1 - 78(5)
ER -